Literature DB >> 26392722

The Role of Procalcitonin Levels in Assessing the Severity of Clostridium Difficile Infection.

Jason Dazley1, Hamid Shaaban1, Shoaib Afridi1, Jihad Slim1.   

Abstract

Entities:  

Year:  2015        PMID: 26392722      PMCID: PMC4557143          DOI: 10.4103/0974-777X.162229

Source DB:  PubMed          Journal:  J Glob Infect Dis        ISSN: 0974-777X


× No keyword cloud information.
Sir, Clostridium difficile-associated disease (CDAD) is the most recognized cause of healthcare-associated infectious diarrhea and a major cause of morbidity and mortality in hospitalized patients.[12] Clinical manifestations range from mild or moderate watery diarrhea to fulminant, pseudomembranous colitis.[3] Because of the heterogeneous presentation of CDAD, early identification of severe illness may be crucial in the institution of prompt and proper management.[45] There is a paucity of research on biomarkers for the diagnosis for CDAD.[6] Procalcitonin (PCT) is a Food and Drug Administration (FDA)-approved biomarker that is produced by numerous cells in the body, specifically in response to bacterial infections (i. e., pneumonia and sepsis).[78] Its role in the identification of severe CDAD has not been validated.[910] This analysis was conducted in order to evaluate the role of PCT levels as a diagnostic adjunct in the identification of severe CDAD. A retrospective chart review was conducted in two inner city hospitals in New Jersey. All patients > 18 years of age admitted between January 1, 2011 and August 2012 who were diagnosed with CDAD were eligible. CDAD was defined as having diarrhea (i. e., more than watery stools/24 h) plus a positive Clostridium difficile stool assay (positive enzyme immunoassay for toxin A/B test or polymerase chain reaction (PCR) test). Only patients who had a PCT level drawn within 24 h of confirmation of CDAD were included. The following data were collected: A. Markers of CDAD severity - white blood cell (WBC) count, serum creatinine, serum albumin, temperature, and blood pressure. b. Risk factors and other variables - age, gender, residence in a nursing home, concomitant suspected or confirmed acute bacterial infection, and Charlson comorbidity score. Severe CDAD was defined as presence of CDAD plus any one of the following: WBC > 15,000 cells/ml, fever (temperature > 38.2°C), and 50% increase in serum creatinine from baseline or hypotension (systolic blood pressure (SBP) < 90 mmHg or mean arterial pressure (MAP) < 60). Logistic regression analysis was done to determine the association between severe CDAD and PCT, as well as the risk factors. Receiver operating characteristic (ROC) curve analysis was done to determine the best cutoff point for PCT. [Figure 1] Fifty-three patients were included in the study, and their characteristics included the following: [Table 1] Mean age in years, 69.2 ± 19 (43.4%); male gender 41.5%; and patients with severe CDAD, 62.3%. Age, gender, concurrent bacterial infection, and residence in the nursing home did not affect PCT's association with severe CDAD.
Figure 1

Logistic regression analysis was done to determine the association between severe CDAD and PCT and receiver operating characteristic (ROC) curve analysis was done to determine the best cut-off point for PCT

Table 1

Patient characteristics

Logistic regression analysis was done to determine the association between severe CDAD and PCT and receiver operating characteristic (ROC) curve analysis was done to determine the best cut-off point for PCT Patient characteristics PCT > 0.5 is a marker to identify severe CDAD; specificity 86.1%, sensitivity 88.2%, positive predictive value (PPV) 93.9%, and negative predictive value (NPV) 75.0%. [Figure 1] [Table 2].
Table 2

Odds ratio for how different variables are associated with severe CDAD

Odds ratio for how different variables are associated with severe CDAD PCT levels at > 0.5 μg/mL appear to be a good indicator of severe CDAD, with a very high PPV. [Table 3] Prospective, larger studies are needed to validate this finding. Further research is needed as to whether following PCT levels may be helpful in determining resolution of the disease, risk of relapse, or predict mortality.
Table 3

PCT > 0.5 as a marker to identify severe CDAD

PCT > 0.5 as a marker to identify severe CDAD
  10 in total

Review 1.  Clinical practice. Antibiotic-associated diarrhea.

Authors:  John G Bartlett
Journal:  N Engl J Med       Date:  2002-01-31       Impact factor: 91.245

Review 2.  Emergence of Clostridium difficile-associated disease in North America and Europe.

Authors:  E J Kuijper; B Coignard; P Tüll
Journal:  Clin Microbiol Infect       Date:  2006-10       Impact factor: 8.067

3.  A pilot randomised controlled trial in intensive care patients comparing 7 days' treatment with empirical antibiotics with 2 days' treatment for hospital-acquired infection of unknown origin.

Authors:  N Scawn; D Saul; D Pathak; B Matata; I Kemp; R Stables; S Lane; A Haycox; R Houten
Journal:  Health Technol Assess       Date:  2012-09       Impact factor: 4.014

Review 4.  Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations.

Authors:  Sofya Tokman; Philipp Schuetz; Stephen Bent
Journal:  Expert Rev Anti Infect Ther       Date:  2011-06       Impact factor: 5.091

5.  Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients.

Authors:  Erik R Dubberke; Kimberly A Reske; Margaret A Olsen; L Clifford McDonald; Victoria J Fraser
Journal:  Clin Infect Dis       Date:  2008-02-15       Impact factor: 9.079

6.  Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003.

Authors:  L Clifford McDonald; Maria Owings; Daniel B Jernigan
Journal:  Emerg Infect Dis       Date:  2006-03       Impact factor: 6.883

7.  Increase in Clostridium difficile-related mortality rates, United States, 1999-2004.

Authors:  Matthew D Redelings; Frank Sorvillo; Laurene Mascola
Journal:  Emerg Infect Dis       Date:  2007-09       Impact factor: 6.883

8.  Procalcitonin levels associate with severity of Clostridium difficile infection.

Authors:  Krishna Rao; Seth T Walk; Dejan Micic; Elizabeth Chenoweth; Lili Deng; Andrzej T Galecki; Ruchika Jain; Itishree Trivedi; Marie Yu; Kavitha Santhosh; Cathrin Ring; Vincent B Young; Gary B Huffnagle; David M Aronoff
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

9.  Bacterial complications of respiratory tract viral illness: a comprehensive evaluation.

Authors:  Ann R Falsey; Kenneth L Becker; Andrew J Swinburne; Eric S Nylen; Maria A Formica; Patricia A Hennessey; Mary M Criddle; Derick R Peterson; Andrea Baran; Edward E Walsh
Journal:  J Infect Dis       Date:  2013-05-09       Impact factor: 5.226

10.  Clostridium difficile surveillance trends, Saxony, Germany.

Authors:  Florian Burckhardt; Anett Friedrich; Dietmar Beier; Tim Eckmanns
Journal:  Emerg Infect Dis       Date:  2008-04       Impact factor: 6.883

  10 in total
  1 in total

Review 1.  Concurrent and Subsequent Co-Infections of Clostridioides difficile Colitis in the Era of Gut Microbiota and Expanding Treatment Options.

Authors:  Mattia Trunfio; Silvia Scabini; Walter Rugge; Stefano Bonora; Giovanni Di Perri; Andrea Calcagno
Journal:  Microorganisms       Date:  2022-06-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.